Medication info
Dapagliflozin and Metformin Extended-Release Tablets 10/1000 mg

Dapagliflozin and Metformin Extended-Release Tablets 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Aju Pharmaceuticals Co., Ltd.
Appearance
Yellow, oval-shaped, film-coated extended-release tablets that are convex on both sides
Packaging
30 tablets/box [6 tablets/PTP x 5]
Approval status
Active

MFDS item code 202300210 · Approved 2023.01.11 · Insurance code 654006070

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or the nearest appropriate therapeutic dose. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dose adjustments made as appropriate. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dose adjustments made as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering drugs. Because changes may cause variations in blood glucose control, any change in treatment of patients with type 2 diabetes should be made under close monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass that resembles a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is more likely to be decreased in elderly patients, this medicine should be used with caution as age increases (see the patient section under '9. Administration to elderly patients' in Precautions for use).

Ingredients

Manufacturer
Aju Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used in combination with dapagliflozin and metformin primarily to improve blood sugar control in adult patients with type 2 diabetes. It is more effective when administered alongside dietary and exercise therapy. In particular, in patients with type 2 diabetes who do not achieve adequate blood sugar control and have cardiovascular disease or risk factors, the impact of this medication on the occurrence of cardiovascular events should be referred to expert guidelines. Overall, this medication helps with blood sugar control and prevention of complications, supporting health management.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or the nearest appropriate therapeutic dose. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dose adjustments made as appropriate. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dose adjustments made as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering drugs. Because changes may cause variations in blood glucose control, any change in treatment of patients with type 2 diabetes should be made under close monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass that resembles a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is more likely to be decreased in elderly patients, this medicine should be used with caution as age increases (see the patient section under '9. Administration to elderly patients' in Precautions for use).

Precautions

This medication is used in the treatment of diabetes and helps control blood sugar levels. While taking this medication, lactic acidosis, which can be life-threatening, may occur very rarely, so attention should be paid to symptoms or conditions. When used with other diabetes medications, hypoglycemia may occur, so blood sugar levels should be monitored carefully. Patients with severely impaired kidney function or acute conditions, dehydration, or severe infections may be at risk from taking this medication and should not use it. Women who are pregnant or breastfeeding should not use this medication, and women of childbearing potential should consult a doctor before use. Elderly patients or those with compromised kidney function should have their kidney function assessed before taking this medication and should be monitored regularly for kidney function and blood pressure during use. This medication may increase the risk of decreased fluid volume or hypotension, especially when taken with antihypertensive medications or diuretics, so caution is needed. Infection symptoms such as genital or urinary tract infections may occur during treatment, and should be reported to a healthcare provider immediately. This medication may lower vitamin B12 levels, so testing vitamin B12 levels is advisable during long-term treatment. Alcohol intake may increase the risk of lactic acidosis, so avoid excessive drinking during treatment. Blood sugar levels may suddenly drop during treatment, so be aware of hypoglycemic symptoms and be prepared to respond if necessary. During surgery or radiologic examinations with contrast agents, discontinue use and check kidney function before resuming. In case of overdose, seek medical attention immediately, and since this medication can be removed by dialysis, dialysis treatment may be helpful if needed. This medication has not been established as safe for children or pregnant women, so it is advisable not to use it for these groups. Caution is needed as dizziness may occur when driving or operating machinery.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • polydipsia
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • lower back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated serum urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal impairment
  • rash
  • diarrhea
  • nausea
  • vomiting
  • reduced vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignancy
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbances
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • pericapsulitis
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. This will help maintain the effectiveness and safety of the medication.

Appearance and packaging

Appearance

Yellow, oval-shaped, film-coated extended-release tablets that are convex on both sides

Package unit

30 tablets/box [6 tablets/PTP x 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.